STOCK TITAN

Vericel (NASDAQ: VCEL) director awarded RSUs and 8,000 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vericel Corp director Heidi Hagen reported routine equity compensation activity. She exercised 3,200 Restricted Stock Units into 3,200 shares of common stock, bringing her direct common stock holdings to 35,050 shares. She also received a new grant of 3,200 RSUs that vest 100% on the earlier of April 29, 2027 or the first Annual Meeting of Stockholders following April 29, 2026. In addition, she was granted stock options for 8,000 shares at an exercise price of $33.43 per share, vesting in equal monthly increments over one year and expiring on April 29, 2036. All transactions reflect awards and exercises rather than open‑market buying or selling.

Positive

  • None.

Negative

  • None.
Insider Hagen Heidi
Role null
Type Security Shares Price Value
Exercise Restricted Stock Unit 3,200 $0.00 --
Grant/Award Stock Option (Right to Buy) 8,000 $0.00 --
Grant/Award Restricted Stock Unit 3,200 $0.00 --
Exercise Common Stock 3,200 $0.00 --
Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct, null); Stock Option (Right to Buy) — 8,000 shares (Direct, null); Common Stock — 35,050 shares (Direct, null)
Footnotes (1)
  1. The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 30, 2025. Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025. No expiration date for this type of award. The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders following April 29, 2026.
RSUs exercised 3,200 shares Restricted Stock Units converted to common stock on April 29, 2026
Common stock holdings 35,050 shares Direct Vericel common stock owned after transactions
New RSU grant 3,200 RSUs Vest 100% on earlier of April 29, 2027 or first Annual Meeting after April 29, 2026
Stock options granted 8,000 options Right to buy Vericel common stock granted April 29, 2026
Option exercise price $33.43 per share Conversion or exercise price for 8,000 stock options
Option expiration April 29, 2036 Scheduled expiration date of granted stock options
Restricted Stock Unit financial
"The shares of common stock were acquired ... as a result of the vesting of Restricted Stock Units (RSUs) granted..."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
RSU financial
"Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation."
Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" with 8,000.0000 derivative shares granted."
Annual Meeting of Stockholders financial
"These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders..."
Exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security" for RSU vesting and option-related activity."
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hagen Heidi

(Last)(First)(Middle)
C/O VERICEL CORPORATION
64 SIDNEY STREET

(Street)
CAMBRIDGE MASSACHUSETTS 02139

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Vericel Corp [ VCEL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/29/2026M3,200A(1)35,050D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit(2)04/29/2026M3,200 (3) (4)Common Stock3,200$00D
Stock Option (Right to Buy)$33.4304/29/2026A8,000 (5)04/29/2036Common Stock8,000$08,000D
Restricted Stock Unit(2)04/29/2026A3,200 (6) (4)Common Stock3,200$03,200D
Explanation of Responses:
1. The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 30, 2025.
2. Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
3. These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025.
4. No expiration date for this type of award.
5. The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company.
6. These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders following April 29, 2026.
/s/ Sean Flynn, as Attorney-in-Fact for Heidi Hagen05/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Vericel (VCEL) director Heidi Hagen report?

Heidi Hagen reported equity compensation activity, including exercising 3,200 RSUs into common stock and receiving new grants of 3,200 RSUs and 8,000 stock options. These are awards and exercises, not open‑market share purchases or sales.

How many Vericel (VCEL) shares does Heidi Hagen hold after these transactions?

After exercising 3,200 Restricted Stock Units into common stock, Heidi Hagen directly holds 35,050 shares of Vericel common stock. This figure reflects the updated position reported in the Form 4 following the April 29, 2026 equity compensation transactions.

What are the terms of Heidi Hagen’s new Vericel (VCEL) RSU grant?

Hagen received 3,200 Restricted Stock Units, each representing one Vericel common share. These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders following April 29, 2026, subject to continued service.

What are the key details of the stock options granted to Heidi Hagen at Vericel (VCEL)?

Hagen was granted stock options covering 8,000 Vericel common shares at an exercise price of $33.43 per share. The options vest over one year in equal monthly increments, contingent on continued service, and are scheduled to expire on April 29, 2036.

Did Heidi Hagen buy or sell Vericel (VCEL) shares on the open market?

The reported transactions do not involve open‑market buying or selling. Instead, they reflect the vesting and exercise of 3,200 RSUs into common stock and the grant of new RSUs and stock options as part of equity compensation.